

# 114101 - Post-marketing safety study to assess the risk of spontaneous abortions in women exposed to Cervarix in the United Kingdom

**First published:** 15/07/2013

**Last updated:** 01/07/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS3310

---

### Study ID

31662

---

### DARWIN EU® study

No

---

### Study countries

 United Kingdom

---

### Study description

This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e. women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix, when compared to a non-exposed cohort, i.e. women with LMP between 120 days and 18 months after the last Cervarix dose. The data collected in the Clinical Practice Research Datalink General Practitioner OnLine Database (CPRD GOLD) in the UK, will be analysed in this study.

---

## Study status

Finalised

## Research institutions and networks

### Institutions

#### Clinical Practice Research Datalink (CPRD)

 United Kingdom

**First published:** 15/03/2010

**Last updated:** 17/01/2025

**Institution**

**Laboratory/Research/Testing facility**

**ENCePP partner**

### Networks

Clinical Practice Research Datalink General  
Practitioner OnLine Database

## Contact details

### Study institution contact

Call Center EU Clinical Trials

Vx.publicdisclosureglobal@gsk.com

Study contact

[Vx.publicdisclosureglobal@gsk.com](mailto:Vx.publicdisclosureglobal@gsk.com)

### Primary lead investigator

Call Center EU Clinical Trials

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Actual: 25/09/2012

---

### Study start date

Actual: 19/11/2012

---

### Data analysis start date

Actual: 12/08/2013

---

### Date of final study report

Actual: 17/03/2014

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

GlaxoSmithKline

## Study protocol

[EPI-HPV-018 VS UK DB \(114101\) Protocol Amendment 1 \(14-Mar-2013\)\\_Protocol Blinding\\_14 June 2013.pdf](#) (812.11 KB)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 3 (required)

## Methodological aspects

### Study type

### Study type list

### **Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

To assess the risk of spontaneous abortion during weeks 1 to 23 of gestation (UK definition) in women aged 15 to 25 years with the first day of last menstrual period (LMP) between 30 days before and 45 days after any dose of Cervarix.

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Anatomical Therapeutic Chemical (ATC) code**

(J07BM02) papillomavirus (human types 16, 18)

papillomavirus (human types 16, 18)

---

**Medical condition to be studied**

Human papilloma virus immunisation

## Population studied

## **Short description of the study population**

Pregnant women were defined based on exposure to Cervarix as recorded in the CPRD GOLD.

1. The exposed cohort included women with the first day of LMP: between 30 days before and 45 days after any Cervarix dose, as requested by the FDA, and between 30 days before and 90 days after any Cervarix dose, as defined in the study EPIHPV-020 and as used for the pooled analysis by Wacholder
  2. The non-exposed cohort included women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome)
- 

## **Age groups**

- Adolescents (12 to < 18 years)
  - Adults (18 to < 46 years)
- 

## **Special population of interest**

Pregnant women

---

## **Estimated number of subjects**

1046

# Study design details

## **Outcomes**

Occurrence of spontaneous abortion during weeks 1-23 of gestation,  
Occurrence of spontaneous abortion during weeks 1-19 of gestation, Occurrence of other pregnancy outcomes up to 12 months after last menstrual period, Baby's death in the first 12 weeks of life.

---

## Data analysis plan

The primary analysis will be the comparison of the risk of spontaneous abortion during the first 23 weeks of gestation and during the first 19 weeks of gestation in the exposed cohort and the non-exposed cohort using a Cox regression model with spontaneous abortion as the dependent variable, a dichotomous exposure as the independent variable and with age at first day of gestation as a covariate. The hazard ratio and its 95% confidence interval (CI) will be derived. The analysis will be done for two risk periods for the exposed subjects: the 30 days before to 45 days after any dose of Cervarix period and the 30 days before to 90 days after any dose of Cervarix period. For subjects with no spontaneous abortion, time-to-event will be censored at: the end of week 23 (or week 19), date of induced or therapeutic abortion, date of death, date of last available pregnancy data whichever occurs first.

## Documents

### Study results

[114101-Clinical-Study-Report-Redact-V1.pdf](#) (1.94 MB)

---

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

## **Data sources (types)**

Electronic healthcare records (EHR)

## Use of a Common Data Model (CDM)

### **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No